by guest www.bloodjournal.org From KEY POINTS 1) A sizable fraction of CLL patients is characterized by the expansion of clonal B cells with anergic features. 2) The constitutive biochemical signature of B cell anergy can be efficiently targeted in CLL for therapeutic purposes Abstract B-Cell Receptor (BCR) triggering and responsiveness have a crucial role in the survival and expansion of Chronic Lymphocytic Leukemia (CLL) clones.
Introduction
Chronic Lymphocytic Leukemia (CLL), a chronic lymphoid malignancy characterized by the accumulation of monoclonal, CD5 + B lymphocytes in peripheral blood (PB), bone marrow (BM) and secondary lymphoid organs, is clinically heterogeneous. Patients may present with an indolent disease and a life expectancy similar to normal individuals or with an aggressive tumour, shorter survival and early treatment requirements 1 . Biological predictors of clinical outcome, such as the mutational status of the immunoglobulin (IG) heavy chain variable genes (IGHV) and the expression of signalling molecule ZAP70 2,3 , suggest a key role for the CLL cell membrane IG in the pathogenesis of the disease. In addition, molecular and functional analyses of the B-Cell
Receptor (BCR) strongly support the hypothesis that a stimulation through the BCR is involved in the selection and expansion of the malignant CLL clone 4, 5, 6 .
In line with this, several groups (reviewed by Stevenson et al. 7 ) have found that a number of molecules along the signalling pathways originating from the BCR are constitutively activated in all CLL patients, providing the basis for effective therapeutic targeting, currently tested in prospective clinical trials (reviewed by Woyach et al. 8 ).
We previously reported that in approximately half of CLL cases leukemic cells constitutively express phosphorylated Extracellular Regulated Kinases 1/2 (ERK1/2) and MAP/ERK Kinases 1/2 (MEK1/2) together with activated Nuclear Factor of Activated T cells c1 (NF-ATc1) transcription factor. Such cases are also characterized by cellular unresponsiveness to sIgM ligation in terms of phosphotyrosine induction 9 . In addition, Mockridge and collegues 10 demonstrated that cells from CLL patients that express low levels of surface IgM fail to mobilize intracellular calcium upon BCR triggering. Taken together, these features recapitulate the biochemical program observed in mouse models of B cell anergy 11 . Anergy 12 is one of the mechanisms that the immune system For personal use only. on October 24, 2017. by guest www.bloodjournal.org From adopts to silence autoreactive B lymphocytes upon low affinity recognition of self antigens (Ag) 13 . The state of BCR desensitization induced by chronic Ag binding in vivo results in cell unresponsiveness when B lymphocytes are further stimulated in vitro by an Ag-like activation 14 . In mouse models, anergized B cells share a common biochemical signature that includes low levels of surface IgM (due to constant BCR internalization and recycling 15 ), elevated basal intracellular calcium concentrations and subsequent constitutive activation of ERK1/2 and NF-ATc1 11, 16 . This biochemical program is not permanent, but it is reversible and lasts as long as B lymphocytes are exposed to the Ag 14 .
All together these observations led us to propose that constitutive activation of MAP kinase signalling pathway along with NFATc1 transactivation represents the molecular signature also of human anergic B lymphocytes and thus that CLL cases presenting this signature may be taken as a human model of leukemic expansions of B cells with anergic properties 9 .
In this manuscript, we investigated the molecular features of the CLL anergic subset (defined as the one that presents constitutive pERK) and we also took advantage of the use of small chemical compounds that specifically block the activation of both ERK1/2 and NF-ATc1. We conclude that anergy induction and maintenance favours the survival of leukemic lymphocytes and may be effectively targeted for therapeutic purposes.
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Material and Methods

Tissue samples and cell purification
Leukemic lymphocytes were obtained from peripheral blood of CLL patients, diagnosed according to the International Workshop on CLL (iwCLL)/National Cancer Institute Working Group (NCIWG) guidelines 17 . All patients were either untreated or off therapy for at least 6 months before the beginning of the study. The following parameters were analyzed for each patient: age, gender, disease stage at diagnosis according to Binet 18 or modified Rai 19 criteria, CD38 expression, IGHV gene mutational status 20 , ZAP70 expression 2 , history of treatment, characterization of disease as progressive or stable as defined by the iwCLL/NCIWG and survival time.
Leukemic cells were purified immediately after blood withdrawal, by negative depletion, using a B-lymphocyte enrichment kit (RosetteSep; StemCell Technologies). Purity of all preparations was always more than 99%, and the cells coexpressed CD19 and CD5 on their cell surfaces as checked by flow cytometry (FC500; Beckman Coulter); preparations were virtually devoid of natural killer (NK) cells, T lymphocytes, and monocytes.
All tissue samples were obtained with approval by the institutional review board of San Raffaele University Hospital (Milan, Italy). Informed consent was obtained in accordance with the Declaration of Helsinki. MEC1 CLL cell line 21 was purchased from DSMZ.
Antibodies and reagents.
Antibodies
For flow cytometry, anti CD19 and anti CD5 were purchased from Beckman Coulter and IgM from Southern Biotechnology. Alexafluo488-pERK1/2 antibody was from BD Biosciences Pharmingen. Cells were analyzed with a FC500 flow cytometer (Beckman-Coulter).
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For Western blot analysis, specific secondary antibodies horseradish peroxidase (HRP)-conjugated, (goat anti-rabbit Ig and goat anti mouse Ig) were purchased from Upstate Biotechnology.
For BCR triggering, goat F(ab) 2 anti-human IgM antibodies were purchased from CALTAG Laboratories.
Inhibition and Stimulation
U0126 was purchased from Calbiochem; CI1040 and AZD6244 were from Selleck Chemicals. For in vitro studies 11R-VIVIT peptide was purchased from Calbiochem, for in vivo experiments the peptide was chemically synthesized by Genescript (purity>98%) and resuspended in water at the concentration of 5mg/ml. NMS6E was provided by Nerviano Medical Sciences.
As positive control for phospho-flow staining, processed murine splenocytes were stimulated with PMA (100 ng/ml, Sigma).
Cell culture and stimuli
Purified lukemic cells were cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine and 15 ug/ml gentamicin (complete RPMI; Invitrogen). Lymphocytes were cultured at the concentration of 3x10 6 cells/ml in the presence or the absence of different stimuli or inhibitors as indicated.
Western blot analysis
Cells were lysed with ice cold Lysis Buffer (NaCl 0.15M, 1% v/v NP40, 1mM EDTA pH=8, 50mM Tris-HCl pH=7) with fresh protease and phosphatase inhibitors cocktail (Roche).
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Whole protein extracts (30 µg) were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDSPAGE), and proteins from gel were electron-transferred onto nitrocellulose membranes and incubated with the indicated antibodies. Antibodies were diluted in a solution of PBS+0,1% Tween (PBST) containing 5% of non fat dry milk or 5% of BSA (Bovin Serum Albumin) according to manufacturers' instructions. Immunoreactivity was revealed by incubation with specific secondary antibodies conjugated with HRP, and was followed by enhanced chemiluminescence (ECL) reaction 
NF-ATc1 activation assay
Nuclear extraction
Nuclear and cytoplasmic extracts were obtained using Nuclear Extract Kit from 
NF-ATc1 ELISA based assay
The level of NF-ATc1 activation was determined by using TransAM transcription factor kit from Active Motif. Nuclear extracts, purified as described in the previous section, were incubated with oligonucleotides containing the NF-AT specific consensus sequence immobilized on a 96-well plate. Active NF-AT contained in nuclear extracts bound specifically to this oligonucleotide and was detected with a specific antibody against NF-AT.
Addition of a secondary antibody conjugated to horseradish peroxidase (HRP) provided colorimetric readout that was quantified by measuring absorbance at 450 nm. To confirm specificity, we also performed competition experiments by adding 2μl of free oligonucleotide to the wells before nuclear extract (data not shown).
Analysis of cell viability and apoptosis
After each different treatment at indicated doses and time points, the percentage of viable cells was determined using the CellTiter-Glo Luminescent Cell Viability Assay kit, according to the manufacturer's instructions (Promega). All measurements were performed in duplicate and the viability of treated cells was normalized to the relative untreated control. 
Intracellular calcium flux
Intracellular calcium flux was measured by using the fluorogenic probe Fluo3AM (Invitrogen) as previously described 10 .
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Briefly, purified leukemic cells (at concentration of 10 7 cells/ml in complete RPMI) were incubated with 4μM of Fluo3-AM and 0.02% (vol/vol) of Pluronic F-127 (Sigma) for 30 minutes at 37°C. Cells were then washed and resuspended at 5x10 6 cells/mL in complete RPMI at room temperature. Cells (250 μL) were warmed to 37°C for 5 minutes prior to acquisition of background fluorescence (i.e, of unstimulated cells), followed by addition of 20 μg/ml goat F(ab) 2 antihuman IgM or IgD (Southern Biotechnology) and data acquisition for a further 5 minutes.
Data were acquired on a BD FACScalibur and analyzed by using the Flowjo software (Tree Star).
In order to calculate the percentage of cells responding to BCR triggering, we first established a baseline fluorescence threshold (T) for each sample (by acquiring samples for 40 seconds without any stimulus) at the fluorescence intensity of the 85th percentile of unstimulated cells. We then calculated the peak percentage of cells that exhibited an increase in fluorescence intensity above the threshold following treatment with anti-IgM/IgD. As previously described 10 , we classified patient as signallers when the percentage of cell responding to anti-IgM stimulation was higher than 5%. 
In vivo experiments
Phospho-Flow Cytometry
ERK1/2 phosphorylation status was analyzed by flow cytometry on processed murine spleens. Briefly, single cell suspensions were fixed in Lyse/Fix Solution (BD Biosciences Pharmingen) for 10 minutes at 37°C. Cells were then washed and permeabilized by using a Perm Buffer (0.5% saponin, 5% FCS, 10mM
Hepes) for 20 minutes at room temperature. Cells were washed and incubated with anti human CD19 and anti human pERK1/2 for 30 minutes at 4°C and analyzed with a FC500 flow cytometer. PMA-stimulated cells for 10 minutes at 37°C were used as positive control (data not shown).
Statistical analysis
Data were compared using either the paired or unpaired Student's t-tests or the nonparametric Mann Whitney test. Comparison of survival curves was performed with the use of the log-rank test. Analyses were performed using GraphPad Prism 4 software (GraphPad Software, San Diego, CA, USA). A Pvalue <0.05 was considered as statistically significant.
Results
Identification of the molecular features of anergy in CLL
Based on our previous observation of the existence of anergic features (i.e. constitutive ERK1/2 phosphorylation and NF-ATc1 activation) in a subset of CLL patients, we started by characterizing an unselected cohort of 52 CLL patients. CLL cases with constitutive phosphorylated ERK1/2 (pERK1/2+) were 23 out of 52, they preferentially showed absence of CD38 expression (p=0,01), low ZAP70 expression (p=0,02) and a more stable clinical course (p=0,007). They also showed an association trend with mutated status of IGHV genes even if this correlation did not reach statistical significance (p>0,05) ( Table 1 and Supplementary Figure 1 ). As expected, at biochemical level constitutive ERK1/2 phosphorylation correlated with higher NF-ATc1 nuclear translocation ( Figure 1A) as leukemic cells from the pERK(+) subset showed a mean NF-ATc1 activation of 80.7 ± 8.2 (N=23) while those from the pERK(-) group had a mean NF-ATc1 activation of 48.4 ± 5.9 (N=29) (p=0,004).
We next aimed at evaluating the ability of CLL cells from the anergic subset to mobilize calcium after stimulation with 20 μ g/mL of soluble Goat F(ab)2 antihuman IgM, as anergic B cells are characterized by BCR desensitization with consequent unresponsiveness to Ag triggering.
As previously reported 10 and as described in Methods Section, patients were considered as able to signal (so called "signallers") through the BCR when more than 5% of cells were able to increase the calcium-associated fluorescence. In detail, 13/16 pERK(+) samples were unable to increase intracellular Ca 2+ upon BCR stimulation and were considered "non signallers" (Figure 1B) 10 . In contrast, 12/16 pERK(-) samples fully responded by mobilizing calcium (p=0,0005). Interestingly, ERK1/2 phosphorylation was associated with a lower expression of sIgM ( Figure 1C, We next aimed at evaluating whether the above-detected features of CLL cells might translate into a higher resistance to apoptosis. To this end, we cultured in vitro leukemic cells from 10 pERK(+) and 9 pERK(-) samples and analyzed spontaneous apoptosis after 24 and 48 hours. As shown in Figure 1D , pERK(+) B cells are more protected from spontaneous apoptosis than pERK(-) cells both at 24 (p=0,001) and at 48 hours (p=0,004). This might possibly indicate that persistent in vivo BCR engagement may be responsible for maintaining survival in pERK(+) cells.
Functional anergy, as shown by BCR desensitization, is a reversible process that can be reverted by simply culturing cells in vitro long enough to allow the removal of BCR occupancy 10,23,14 . Thus we next aimed at evaluating whether the biochemical features associated with anergy might also be reversible and might correlate with the changes in the response through the BCR. To this end, we cultured CLL cells from 6 pERK(+) cases and from 4 pERK(-) cases for 48 hours and we started measuring ERK1/2 phosphorylation, NF-ATc1 and sIgM changes over time. Both ERK (Figure 2A) and NF-ATc1 (Figure 2B) activation were lost upon culture and this effect was accompanied by the reexpression of sIgM ( Figure 2C) . As expected, cultured leukemic cells which had lost the biochemical features of anergy regained the ability to fully respond to BCR triggering (Figure 2A, left panel) . On the other hand, no changes were observed in the case of pERK(-) samples (Supplementary Figure 2) .
Targeting anergic BCR signalling pathways: how to reprogram functional response
Based on these evidences (Figure 2) , we then asked whether the direct inhibition of the signalling molecules active in the biochemical program of anergy could also have an effect on the reversal of BCR responsiveness.
To this end, we used different small chemical inhibitors including: a) U0126 and CI1040 that specifically target the activation of MEK1/2, the direct upstream kinase of ERK; b) NMS6E, a new generation ERK1/2 inhibitor; c) a cell permeable version of VIVIT, an inhibitory peptide that blocks NF-AT nuclear translocation. As shown in Supplementary Figures 3A, B, C, treatment with the different compounds is able to block the activation of each specific target after short-term incubation (maximal inhibition observed after 1 hour).
In addition, time course experiments revealed that exposure to VIVIT not only inhibited NF-AT nuclear translocation, but also blocked ERK1/2 phosphorylation (maximal inhibition observed after 4 hours of treatment, Figure 3A) . Conversely, treatment with U0126 induced inhibition of NF-AT activation (maximal inhibition at 6 hours, Figure 3B ) besides pERK blockade.
To verify whether the direct blockade of ERK and NF-AT might restore the ability of anergic cells to fully respond to antigen-like stimulation, we pre- (Figure 5D) . The effect correlated also with NF-AT activation status (29.5% ± 7.5 a mean survival for NF-AT(+) group of and 53.6% ± 6.1 mean survival for the NF-AT(-), p=0,02; n=20) ( Figure 5E ).
Taken together, our results demonstrate that the presence of anergic features is associated with the maintenance of cell survival in CLL and that the specific inhibition of the signalling pathways involved in this biochemical program may selectively induce cell death among pERK(+) patients.
As our results (Figure 3A-B) suggested that MAPK and NF-AT are interconnected, we tested whether the concomitant inhibition of both pathways could modify the pro-apoptotic effect on CLL cells. To this end, we treated pERK(+)/NF-AT(+) cells (n=6) with 10 µM of each inhibitor (NMS6E, U0126, VIVIT) alone or in combination and we analyzed cell viability after 48 hours.
The simultaneous inhibition of both MAPK and NF-AT signalling did not enhance apoptosis (Figure 5F) , thus confirming that both molecules lay on the same signalling pathway of anergy, that is effectively blocked by single inhibitors.
NF-ATc1 inhibition slows leukemia progression in vivo.
To strengthen our in vitro data, we evaluated the effect of NF-AT inhibition in vivo, following VIVIT administration in the xenograft Rag2 -/γc -/mouse model subcutaneously transplanted with the CLL cell line MEC1 22 , that shows specific features of anergy (constitutive pERK1/2, constitutive NF-ATc1 nuclear translocation 9 ).
Mice were subcutaneously injected with 10x10 6 cells and then challenged with VIVIT (10mg/kg) 25 or with vehicle alone starting from day 10 after tumour injection. The effect of the inhibitor was monitored by tumour volume growth.
Mice were sacrificed when the tumour volume reached 1000 mm 3 or when the animals showed clinical signs and symptoms.
VIVIT administration delayed tumour growth (Figure 6A , day 33, day 38, day 40 p<0,05) and improved mice survival ( Figure 6B ) the median survival of VIVIT treated group being 52.5 days as compared to the untreated group (46 days; p=0,006).
At the time of sacrifice, organs and tissues (spleen, bone marrow, peritoneal exudate, lymph nodes when enlarged and peripheral blood) were collected, processed and stained for human CD19 to identify human leukemic cells.
To further explore in vivo anergy reversal, cells processed from spleen were also stained for pERK1/2 (Figure 6C) . VIVIT treatment significantly decreased ERK1/2 phosphorylation in CD19 + cells, indicating that the biochemical anergic program can be reverted also in vivo, in a mouse model of CLL, and anergy reversal is associated with a survival benefit for the animals.
Discussion
For many years CLL has been considered a leukemia of functionally inactive B lymphocytes. In apparent contrast, more recently it has been shown that a portion of cases is actually responsive to external stimuli including the activation though the BCR. That notwithstanding, a sizable fraction of CLL patients are indeed characterized by the expansion of clonal B cells that have anergic features 5, 9, 10 . Anergy is one of strategies adopted by the immune system to silence autoreactive B cells, the others being clonal deletion and tolerance.
Based mainly on studies in transgenic mouse models 26 A recent work 27 demonstrated that NF-ATc1 is constitutively activated in all CLL samples tested. We here show that this activation occurs at variable levels in the different patients. Interestingly, constitutive phosphorylation of ERK1/2 kinases correlates with higher NF-ATc1 activation, suggesting that the different basal levels of NF-ATc1 activation, being higher in the pERK(+) subset (Figure 1A) , might induce a different downstream transcriptional program that culminates in the induction of B cell anergy, due to a "dosage-dependent" activation of the transcription factor and/or to different NF-AT-interacting partners 28 . All these issues could be investigated in the future by the direct analysis of the NF-ATc1 interacting proteins. The actual relationship between these two signalling activities deserves further investigation.
We also show that by inhibiting the signalling molecules involved in anergy we can revert anergy both in vitro and in vivo, as revealed by the restoration of BCR responsiveness following the loss of ERK phosphorylation and NF-AT nuclear translocation. Reversal of anergy could also be obtained by simply culturing cells for 48 hours after blood withdrawal and this paralleled the delayed onset of the apoptosis among anergic leukemic lymphocytes in vitro. This is in line with the hypothesis that chronic antigen engagement may be responsible also for a prolonged cell survival in vivo. It came then with no surprise that by using of a number of small chemical inhibitors that specifically target, at different levels, the anergy-related pathways we were able to induce are maintained in a cell line without any apparent ongoing antigen stimulation is unclear. A plausible explanation is that yet unknown gene abnormalities acquired during the immortalization process may maintain the anergic program in an antigen-independent fashion. Alternatively it might be speculated that self antigens able to stimulate the MEC1 BCR are released by apoptotic cells in culture, Mice treated with VIVIT had a delay in tumour growth and an increased survival compared to the untreated group. Of interest, leukemic cells from treated mice showed a decreased expression of ERK1/2 phosphorylation, thereby paralleling and confirming our in vitro findings. These data further support the idea that blocking anergic pathways may be highly effective not only in vitro but also in vivo with an obvious potential clinical implications at least for the subset of patients whose cells are characterized by anegic features.
The use of small molecules inhibitors is now becoming extremely promising (see BTK and PI3K inhibitors) due to the specific targeting and the limited side effects. For this reason, anergy reversal could be envisaged of potential use in For personal use only. on October 24, 2017. by guest www.bloodjournal.org From the sizable fraction of patients who have a rather indolent still progressive disease. It may be asked whether the risk exists that the reversal of B cell anergy in vivo might lead to a more aggressive disease, considering that absence of ERK1/2 phosphorylation is associated with a worse prognosis. However, according to our findings it is reasonable to believe that blocking B cell anergy in vivo would trigger an even higher apoptosis rate than that observed in vitro.
This effect could be due to the combination of two different mechanisms: on one side the inhibition of a survival program (anergy) and on the other side the restoration of the signalling capacity, the latter being involved in the induction of apoptosis in CLL, as previously reported [29] [30] [31] .
In conclusion, our results demonstrate that a subset of CLL patients, identified by the constitutive ERK1/2 phosphorylation, is characterized by the abnormal expansion of B cells with anergic properties. In these cells the constitutive activation of ERK and NF-ATc1, leading to functional unresponsiveness, can be efficiently targeted and cells regain their ability to respond to BCR stimulation. More importantly, B-cell anergy reversal is followed by apoptosis induction possibly opening new perspectives in the clinical management of these patients.
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